Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2009: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Research Abstract |
Hepatitis virus C is an oncogenic virus to induce liver cirrhosis and hepatocellular carcinoma via chronic inflammation. Pegylated-inferferon (PEG-IFN) and ribavirin (RBV) combination therapy is an established therapy, but its efficacy is still low. Based on this background, identification of unknown biomarkers in relation to therapeutic efficacy was carried out by using of the mass spectrometry. This research would be helpful to develop a future therapy.
|